Analysts/Institutional Investor Meet/Con. Call Updates

-. :» Poly Medicure Limited IP OLYMED Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate, Phase-Ill, New Delhi - 110 020 (INDIA} T: +91-11-33550700, 47317000 E: info@polymedicure.com W: polymedicure.com CIN:L40300DL1995PLC066923 Date: 11th November, 2026 Scrip Code: -531768 Scrip Code: - POL YMED The Manager, The Manager BSE Limited, National Stock Exchange of India Limited Department of Corporate Services, Exchange Plaza, Plot No. C/1-Block-G Phirozee Jeejeebhoy Towers, Bandra Kurla Complex, Bandra(E), Dalal Street, Mumbai-400001. Mumbai-400051. Subject: Submission of Transcript for Q2-FY27 Earning Conference Call under the SEBI (Listing Obligation and Disclosure Requirements), Regulation, 2015 Dear Sir/ Madam, Pursuant to Regulation 30(6) of SEBl (Listing Obligation and Disclosure Requirements) Regulations, 2015, we hereby submit Transcript of the investor Meet/Call held on 05th November 2026, on the Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026, on Standalone and Consolidated basis, which were considered and approved by the Board of Directors of the Company, at its meeting held on 05th November, 2026. This is for your information and record. Thanking You, You rs Sincere!y For Poly Medicure Limited A vinash Chandra Company Secretary M. NP. A32270 Encl: As above Plants : Plot No. l 04-105 & 115-116-117, Sector-59, HSIIDC Industrial Area, Ballabgarh, Faridabad -121004, Haryana (INDIA) Plot No. 33-34, Sector-68, IMT. Faridabad-121004, (Haryana) INDIA T:+91-129-4287000, 3355070 “Poly Medicure Limited Q2 & H1 FY27 Earnings Conference Call” November 05, 2026 MANAGEMENT: MR. HIMANSHU BAID – MANAGING DIRECTOR – POLY MEDICURE LIMITED MR. NARESH VIJAYVERGIYA – CHIEF FINANCIAL OFFICER – POLY MEDICURE LIMITED MR. RAHUL GAUTAM – PRESIDENT, STRATEGY AND CORPORATE DEVELOPMENT – POLY MEDICURE LIMITED Page 1 of 16 Poly Medicure Limited November 05, 2026 Moderator: Ladies and gentlemen, good day and welcome to the Poly Medicure Limited Q2 FY27 and Half Year FY27 Earnings conference Call. As a reminder, all participant lines will be in the listen- only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. Today on this call, we have with us the senior management team of the company represented by Mr. Himanshu Baid, the Managing Director, Mr. Naresh Vijayvergiya, CFO, Mr. Rahul Gautam, President, Strategy and Corporate Development. I would now like to hand the conference over to Mr. Himanshu Baid. Thank you and over to you, sir. Himanshu Baid: Thank you very much. Good evening, everyone, and I welcome you all to Q2 and H1 FY27 Earnings Call. I sincerely thank all of you for being here today. Before we get into the financial performance, I want to highlight few strategic updates since our last earning call. We are on track to optimize Medyneo, our subsidiary in Brazil. We had mentioned in our last call that Mr. Renato Rocha has joined as a CEO of the company, Polymed Brazil operations. We have also started dispatching our goods, first shipments to Brazil, the new subsidiary in October. This is a vital step for us to service our customers in Brazil, which is one of our key markets. We also established a direct presence in the U.K. This has been done to capture new opportunities under the India-UK FTA agreement. We are already working on three important projects. Hopefully, the first project will go live in quarter 1, the second one, the quarter 4 of this current financial year, the next one in quarter 1, and then the third one is anticipated in quarter 3 of the next financial year. So we have three important new projects going on other than what we are currently doing in the U.K. market. So, these are some important initiatives we have taken. We also see similar opportunities in other parts of Europe under India-EU trade agreement, which is going to be operationalized soon. So we are working on building some direct presence in some of the key markets in near future. So, these are some of the important initiatives I just wanted to call out early. Now on the financial performance summary, starting on our standalone performance, which remains the core for the group. For the half year, revenue was INR919 crores, up 15%, with domestic revenue of INR318 crores growing by almost 20%, international revenue of INR595 crores growing around 12.5%. Gross profit was INR645 crores, up 17%, with a margin expanding by 111 basis points to 70.1%. Operating EBITDA was INR255 crores, up 20%, reflecting the operating leverage in the business. Profit after tax was INR180 crores. For the quarter, revenue was INR488 crores, up 17%, with domestic revenue at INR172 crores growing 22%, and international revenue at INR313 crores growing at 15%. Page 2 of 16 Poly Medicure Limited November 05, 2026 Gross profit was INR336 crores, reflecting a gross margin of 68.9% with an absolute growth of 16%. Operating EBITDA was INR134 crores with EBITDA margin of 27.4% with an absolute growth of 20%. PAT for the quarter was INR92 crores. Our domestic business continues a strong growth trajectory with a growth of 22% in quarter and more than 19% for the half year, broadly in the lines of our guidance of around 20% given in the beginning of the year. Taken together, we are seeing high growth across all verticals, not only our established verticals like infusion therapy and blood management, but also on the newer verticals. Our export business deserves a particular attention. International revenue grew by 15% in quarter 2 versus 10% in quarter 1, reflecting improving growth trajectory. Export revenue grew by 12.5% for the half year, once we add up the two quarters. We are confident that the revenue recovery that we had spoken about earlier showing up consistency in the numbers. In international markets, we have added 30 new customers in last six months, deepened relationship with existing customers by increasing our share of revenue and cross-selling new products to them. On the gross profit front, our gross margins increased by 111 basis points to 70.1% in H1, with a gross profit growing around 17%. As you may recall that in the beginning of the year, we had guided for an impact of 200 to 300 basis points in gross margin due to increase in raw material prices on account of ongoing West Asia crisis. We have effectively mitigated that risk by proactively managing inventory, taking calibrated price hikes, and focusing on selling high-value products. We reported a PAT of INR180 crores in H1, reflecting a margin of 18.6%. For Q2, the PAT was INR92 crores, reflecting a margin of 18.1%. Coming on the consolidated picture for the half year, revenue was INR1,106 crores, up 31%. Excluding the impact of acquisition, organic consolidated revenue grew by 14%, led to continuous strong growth in India and Europe, which grew by 19% and 29%, respectively. Gross profit was INR793 crores, up 36%. The margin expanding by 270 basis points to 71.7% as the better margin profile of acquired businesses and greater contribution in higher value-added products continue to lift group's gross margin. Operating EBITDA was INR266 crores, up 19%. Profit after tax was INR180 crores on H1 basis. It is important to know that H1 operating EBITDA of INR266 crores also absorbs the set-up cost for our new U.K. and Brazil subsidiaries. For the quarter, consolidated revenue was INR581 crores, up 31%. Gross profit was INR407 crores, up 32%. Operating EBITDA was INR139 crores, up 20%. PAT, our profit after tax was INR95 crores. Let me give you a quick update on each of the business segments. Infusion therapy grew 11% to INR542 crores in H1, 12% to INR284 crores in Q2, with domestic growing in this segment 20% both in H1 and Q2. Orthopaedics contributed to INR92 crores in H1 and INR43 crores in Q2, reflecting consolidati [Showing first 8,000 characters — download PDF for full document]